Re: James P. Buteau, Daniel Moon, Michael T. Fahey, et al. Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings on Multiparametric MRI (PRIMARY2): A Multicenter, Non-inferiority, Phase 3, Randomized Controlled Trial. Lancet Oncol 2026;27:839–848
Publication date: November 2026 Source: European Urology, Volume 90, Issue 5 Author(s): Alessandro Uleri, Michael Baboudjian, Giovanni Lughezzani, Guillaume Ploussard
Re: James P. Buteau, Daniel Moon, Michael T. Fahey, et al. Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings on Multiparametric MRI (PRIMARY2): A Multicenter, Non-inferiority, Phase 3, Randomized Controlled Trial. Lancet Oncol 2026;27:839–848. // European Urology. – URL: https://www.sciencedirect.com/science/article/pii/S0302283826022694?dgcid=rss_sd_all
Re: James P. Buteau, Daniel Moon, Michael T. Fahey, et al. Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings on Multiparametric MRI (PRIMARY2): A Multicenter, Non-inferiority, Phase 3, Randomized Controlled Trial. Lancet Oncol 2026;27:839–848. European Urology. https://www.sciencedirect.com/science/article/pii/S0302283826022694?dgcid=rss_sd_all
“Re: James P. Buteau, Daniel Moon, Michael T. Fahey, et al. Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings on Multiparametric MRI (PRIMARY2): A Multicenter, Non-inferiority, Phase 3, Randomized Controlled Trial. Lancet Oncol 2026;27:839–848.” European Urology.
@article{article45399,
title = {Re: James P. Buteau, Daniel Moon, Michael T. Fahey, et al. Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings on Multiparametric MRI (PRIMARY2): A Multicenter, Non-inferiority, Phase 3, Randomized Controlled Trial. Lancet Oncol 2026;27:839–848},
journal = {European Urology},
url = {https://www.sciencedirect.com/science/article/pii/S0302283826022694?dgcid=rss_sd_all}
}
Objective To assess prostate‐specific antigen (PSA) testing according to income, age, and region of residence in Sweden. Patients and Methods We conducted a nationwide, population‐based open cohort study of men aged 40–90 years in...